加载中
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
前收盘价
US$3.18
−US$0.04 · -1.24%
盘中时间采用ET。市场数据可能有所延迟。
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
日内区间
当前US$3.18
52周区间
当前US$3.18
盘中时间采用ET。市场数据可能有所延迟。
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
日内区间
当前US$3.18
52周区间
当前US$3.18
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 575.95万 USD | 1189.86万 USD | 1270.53万 USD | 1464.91万 USD | 3203.89万 USD |
| 销售、一般及管理费用 | 934.35万 USD | 994.98万 USD | 1041.43万 USD | 1058.22万 USD | 1332.67万 USD |
| 营业费用 | 1510.3万 USD | 2184.84万 USD | 2311.96万 USD | 2523.13万 USD | 4536.57万 USD |
| 利息收入 | 94.81万 USD | 127.2万 USD | 143.7万 USD | 55.69万 USD | 1.65万 USD |
| 利息支出 | — | 456.2万 USD | 828.3万 USD | 740.7万 USD | 632.7万 USD |
| 折旧和摊销 | 5442 USD | 2.25万 USD | 3.1万 USD | 8513 USD | 10.18万 USD |
| 营业利润 | −1510.3万 USD | −2184.84万 USD | −2311.96万 USD | −2523.13万 USD | −4536.57万 USD |
| 净利润 | −2.93亿 USD | 143.89万 USD | −3000.54万 USD | −3210.87万 USD | −4990.6万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$10.00
上涨空间 214.47%价格历史记录不可用
最高：US$10.00平均的：US$10.00最低：US$10.00| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2022年6月21日 | 1:8 | — | — |
已生效 2022年6月21日
1:8
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI641.34万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM271.99万0.00%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF242.63万0.00%954亿 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO89.54万0.00%180亿 USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO70.62万0.01%139.17亿 USD0.24%US$356.78+0.94%
iShares Micro-Cap ETFIWC36.91万0.03%13.17亿 USD0.60%US$183+0.11%
Vanguard Russell 2000 Growth ETFVTWG11.61万0.01%17亿 USD0.06%US$260.49+0.91%
Invesco NASDAQ Future Gen 200 ETFQQQS8.31万0.37%2275.83万 USD0.20%US$42.145+1.39%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGInvesco NASDAQ Future Gen 200 ETFQQQSAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
